Calliditas Therapeutics ABNASDAQ:CALT
- LAST PRICE18.5000
- TODAY'S CHANGE (%)0.3000 (1.6484%)
- Bid / Lots17.0000/ 15
- Ask / Lots21.8000/ 1
- Open / Previous Close18.8300 / 18.2000
- Day Range
- 52 Week Range
- Volume1,459
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CALT |
|---|---|---|
| 10:15 ET | 100 | 18.83 |
| 11:26 ET | 387 | 18.5 |
Today
Calliditas Therapeutics' 2023 Annual Report Published, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesCalliditas Announces Positive NefIgArd Open Label Extension Results, from 15 hours ago by Dow Jones
15 hours ago by Dow Jones
Apr 18, 2024
Press Release: Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024, from 7:10AM ET on Thursday Apr 18, 2024 by Dow Jones
7:10AM ET on Thursday Apr 18, 2024 by Dow JonesCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024, from 7:10AM ET on Thursday Apr 18, 2024 by Dow Jones
7:10AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 9, 2024
Calliditas Therapeutics to Attend Conferences in April, from 7:22AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:22AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Calliditas Therapeutics AB | 549.5M | -11.5x | --- |
Assembly Biosciences Inc | 72.8M | -1.0x | --- |
Incannex Healthcare Inc | 36.2M | -5.9x | --- |
Hanyuan Biotech International Inc | 539.4K | 0.0x | --- |
Scorpius Holdings Inc | 5.8M | -0.1x | --- |
TherapeuticsMD Inc | 21.7M | -2.6x | --- |
Company Information
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Contact Information
- Headquarters
- D5, Kungsbron 1,STOCKHOLM, Sweden 111 22
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Elmar Schnee
- Chief Executive Officer
- Renee Aguiar-Lucander
- Chief Financial Officer
- Fredrik Johansson
- President - North America
- Andrew Udell
- Vice President - Regulatory Affairs
- Frank Bringstrup
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $549.5M |
|---|---|
Revenue (TTM) | $111.6M |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-1.61 |
Book Value | $1.15 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
